We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Lipid Vesicles Replace Blood in New Bacteria Test

By LabMedica International staff writers
Posted on 04 Oct 2017
Beta-hemolytic bacteria are those pathogens that are frequently to blame for illnesses that are spread among school children like Streptococcus, or those like Listeria that cause many foodborne illnesses. More...
The current test involves streaking a patient sample onto blood agar plates.

Tests do exist for the detection of particular beta-hemolytic species; however, these approaches are commonly based on the detection of genetic or antigenic determinants and not beta-hemolysis. Examples include the antibody–antigen tests, nucleic acid-based assay and more recent approaches using bacteriophages engineered with reporters.

Scientists at the Temasek Life Sciences Laboratory (Singapore) and their colleagues used the original blood agar test as inspiration for their new one. In the new assay, they placed fluorophores inside liposomes, which are lipid vesicles that have been used for controlled drug release. While in the liposome, the fluorescent molecules are packed together and are quenched, or dark, but when in the presence of beta-hemolytic bacteria, the liposome is broken open, the molecules are released, and they fluoresce.

The investigators used bacterial strains which were streaked on sheep blood agar and incubated at 37 °C overnight to check for hemolytic activity. The new test, called BETA, distinguished beta-hemolytic bacteria from control bacteria with 100 % accuracy in six hours on plates, and with 99% accuracy in liquid broth in an hour. The scientists say the method is rapid and cost-effective, which makes it ideal for diagnostics in developing countries. They also noticed that colony fluorescence associated with beta-hemolysis was qualitatively different from background fluorescence associated with control bacteria.

The authors concluded that BETA’s timeliness opens the door to applications once limited by the tardiness of blood agar cultures. With increased speed, gold standard throat cultures based on BETA can now be used as a first-choice diagnostic test (as opposed to a confirmatory assay) for bacterial pharyngitis. BETA’s scalable form-factor (multiwell plates) and low reagent costs (∼USD 0.02 per assay) make it suitable as a sensitive high-throughput triage method for in-plant food safety testing to complement pathogen-specific assays such as phage detection. The study was published on September 20, 2017, in the journal ACS Sensors.

Related Links:
Temasek Life Sciences Laboratory


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
All-in-One Molecular System
AIO M160
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: The Avantect Pancreatic Cancer Test combines epigenomic, genomic, and glycan biomarkers with machine learning to detect pancreatic cancer-associated signals in blood (Photo courtesy of ClearNote Health)

Multiomic Blood Test Supports Noninvasive Monitoring and Subtyping in Pancreatic Cancer

Pancreatic ductal adenocarcinoma remains difficult to detect early and monitor during treatment, particularly in patients with homologous recombination defects. Clinicians also have limited noninvasive... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.